LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.810-3.010 for the period, compared to the consensus estimate of 2.610. The company issued revenue guidance of $276.0 million-$284.0 million, compared to the consensus revenue estimate of $271.3 million. LeMaitre Vascular also updated its Q1 2026 guidance to 0.640-0.690 EPS.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $7.64 on Friday, hitting $106.05. The company had a trading volume of 176,303 shares, compared to its average volume of 173,996. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of 42.18, a P/E/G ratio of 2.03 and a beta of 0.72. The stock has a 50 day moving average price of $86.55 and a 200 day moving average price of $88.30. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $115.33. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. The business had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s payout ratio is 31.87%.

Wall Street Analyst Weigh In

LMAT has been the topic of several recent research reports. Roth Mkm reiterated a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Barrington Research lifted their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Citizens Jmp boosted their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $106.50.

Key LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat expectations: LMAT reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M vs. $62.98M, with revenue up 15.7% year-over-year — a clear operational upside that supports earnings momentum. LeMaitre Q4 2025 Financial Results
• Positive Sentiment: Management raised guidance: Q1 EPS guided to $0.640–0.690 (vs. $0.620 consensus) and FY2026 EPS to $2.810–3.010 (vs. $2.61 consensus), plus higher revenue range — that forward raise is likely the primary bullish catalyst. LeMaitre (LMAT) Stock Trades Up, Here Is Why
• Positive Sentiment: Dividend increased 25% to $0.25 quarterly (annualized yield ~1.1%) — signals cashflow strength and returns capital to shareholders. Dividend Announcement
• Positive Sentiment: Analyst bullishness: Roth MKM reaffirmed “buy” and raised PT to $117; Citizens JMP raised PT to $118 with a market outperform — these upgrades can support further upside. Analyst Upgrades
• Neutral Sentiment: Earnings call and transcript provide color on growth drivers and execution (useful for investors but not an immediate price trigger). Q4 2025 Earnings Call Transcript
• Negative Sentiment: Mixed analyst picture and valuation friction: Wells Fargo raised its PT to $94 but kept an “equal weight” rating (below current levels), and Barrington’s $105 PT is roughly in line or slightly below recent prices — conflicting targets can prompt profit-taking. Mixed Analyst Targets
• Negative Sentiment: High valuation and recent run: LMAT trades with a high P/E (~42.5) and near its 52‑week high, so even positive news may trigger short-term selling as investors lock in gains. Valuation & Price Context

Institutional Trading of LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in LMAT. Goldman Sachs Group Inc. grew its stake in LeMaitre Vascular by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after purchasing an additional 231,157 shares during the period. Millennium Management LLC increased its holdings in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares in the last quarter. First Trust Advisors LP raised its stake in shares of LeMaitre Vascular by 13.4% in the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after purchasing an additional 111,193 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after purchasing an additional 105,921 shares in the last quarter. Finally, Algert Global LLC boosted its position in shares of LeMaitre Vascular by 356.3% during the third quarter. Algert Global LLC now owns 66,268 shares of the medical instruments supplier’s stock valued at $5,799,000 after buying an additional 51,744 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.